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Background: Invasive techniques are still required to distinguish between uncomplicated and complicated forms
of CD.
Methods: We set out to investigate the potential use of novel serum parameters, including IL-6, IL-8, IL-17, IL-22,
sCD25, sCD27, granzyme-B, sMICA and sCTLA-4 in patients diagnosed with active CD, CD on a GFD, Refractory
coeliac disease (RCD) type I and II, and enteropathy associated T-cell lymphoma (EATL).
Results: In both active CD and RCDI-II elevated levels of the proinflammatory IL-8, IL-17 and sCD25 were observed.
In addition, RCDII patients displayed higher serum levels of soluble granzyme-B and IL-6 in comparison to active CD
patients. In contrast, no differences between RCDI and active CD or RCDII were observed. Furthermore, EATL
patients displayed higher levels of IL-6 as compared to all other groups.
Conclusions: A series of novel serum parameters reveal distinctive immunological characteristics of RCDII and EATL
in comparison to uncomplicated CD and RCDI.
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Immunological and biochemical parametersBackground
Coeliac disease (CD) is a chronic immune-mediated in-
flammation of the small intestine caused by a permanent
state of intolerance to ingested gluten proteins affecting
genetically susceptible individuals. Its hallmarks, lympho-
cytic infiltration of the lamina propria, expansion of the
intraepithelial lymphocyte (IEL) population, hyperplasia of
the crypts and atrophy of the villi are mediated by the
interplay between an innate and adaptive immune re-
sponse against gluten [1]. The complex of deamidated
gliadin peptide interacting with the HLA-DQ2 and/or –
DQ8 heterodimers on antigen presenting cells, is capable
of activating the lamina propria T-helper lymphocytes,
thereby initiating antibody production and a gluten-specific
pro-inflammatory type 1 T-cell response (Th1) [1]. Th1* Correspondence: g.tack@vumc.nl
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reproduction in any medium, provided the orcells play an important role in pathogenesis of CD by
secreting interleukin-2 (IL-2) that induces proliferation
of T-lymphocytes and, in particular, by secreting the
pro-inflammatory cytokine interferon-gamma (IFN-γ) [2].
Furthermore, recent evidence has indicated that Th17 cells
play a pathogenic role in CD [3-5]. In addition, interleukin-
15 (IL-15) activates a cytotoxic response of intra-epithelial
lymphocytes through IFN-y release and upregulation of
NKG2D. In combination with epithelial stress, the NKG2D
ligand MHC Class I chain-related A (MICA) is upregulated
by enterocytes [6,7]. The interaction of MICA and NKG2D
induces enterocyte destruction by IELs.
A gluten-free diet (GFD) results in mucosal recovery in
the majority of patients, who are referred to as uncompli-
cated CD-patients. However, a small subset of adult onset
CD patients fails to regain intestinal homeostasis after
elimination of dietary gluten, or symptoms recur after ini-
tial response [8]. After careful evaluation of dietary compli-
ance and exclusion of other possible disease-entitiesd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fer from refractory coeliac disease (RCD) [9]. RCD is con-
sidered a complicated form of CD, and is divided into type
I (RCDI), when patients lack an aberrant IEL population,
or type II (RCDII) in which a substantial (>20%) aberrant
IEL population is found in the small intestinal mucosa
[10,11]. An aggressive type of lymphoma which carries a
dismal prognosis, the enteropathy-associated T-cell lymph-
oma (EATL), is thought to arise from this aberrant IEL
population. An interesting observation is that both aber-
rant IELs as well as EATL cells display a cytotoxic pheno-
type and contain high levels of granzyme-B [12,13], which
could therefore serve as a marker for complicated CD.
In consequence of a good response to immunosuppres-
sive therapy, RCDI patients have a better prognosis than
RCDII patients [14-17]. Therefore, early identification of
CD patients developing RCDII and/or EATL enables early
intervention, which will likely reduce morbidity and
mortality.
Currently, antibodies against tissue transglutaminase
(TGA), anti-endomysium (EMA) and deamidated gliadin
peptides (DGPA) provide valuable and generally
accepted serum parameters for the diagnosis and follow-
up of uncomplicated CD. However, these antibodies are
of no use in predicting and monitoring both types of
RCD and EATL, implying that histological and flow
cytometric analysis of duodenal biopsies are still
required to distinguish between the uncomplicated and
complicated forms of CD. Additional serum markers
could potentially provide us with a minimal-invasive,
easy applicable test without the need to perform a
gastro-duodenal endoscopy. In addition, immunological
markers in the peripheral blood could provide more
insight in the similarities and differences of the patho-
physiology underlying the CD spectrum.
Therefore, in the present study we evaluated several
immunological and biochemical parameters in sera
from the five stages of CD, including active CD
(ACD), CD on GFD, RCDI-II and EATL, for their abil-
ity to differentiate between complicated and uncompli-
cated forms, and secondly, to gain insight in the
pathophysiological relations between these disease en-
tities. For this purpose, we analysed serum levels of
the inflammatory cytokines IL-6, IL-8, IL-17and IL-22,
the T-cell activation factors soluble (s)CD25 (IL2R-alpha)
and sCD27, the T-cell dysregulation factor sCTLA-4,
shown previously to be up-regulated in different auto-
immune diseases, the cytotoxic T-cell parameter gran-
zyme-B, and sMICA, previously shown to be associated
with the presence of epithelial stress and malignancies.
Methods
A retrospective cohort study was conducted at a tertiary
referral centre for coeliac disease in The Netherlands.Patients previously diagnosed with (complicated) CD in
the VU medical center were identified and included in
our study when stored serum samples at time of diagno-
sis were available. Overall, 92 blood samples collected
for diagnostic purposes between 1997 and 2010 were
included. Serum levels of a substantial number of im-
munological markers were determined in the five differ-
ent subsets of CD. In addition, results from several
biochemical parameters of this cohort at time of diagno-
sis were collected from the electronic patient file in our
centre.
Patients
CD diagnosis was based on the ESPGHAN guidelines
[18]. All patients included in the active CD group had
positive EMA and/or TGA, and histological abnormal-
ities grade III according to the modified Marsh classifi-
cation consisting of intra-epithelial lymphocytosis, crypt
hyperplasia and some degree of villous atrophy [19]. Fur-
thermore, serum samples of these patients at time of an
inactive phase of CD were collected. Remission of dis-
ease (GFD group) was defined by the disappearance of
one or both CD antibodies upon a GFD, and if a gastro-
duodenal endoscopy with subsequent collection of biop-
sies was performed during follow-up, normalisation of
mucosal abnormalities (Marsh 0 or I) was required.
Patients included in the RCD group had persisting or re-
curring symptoms and small intestinal villous atrophy,
despite strict adherence to a GFD for at least one year
(assessed by a dietitian and negative TGA/EMA). The
clinically validated cut-off value of more than 20% of the
IELs expressing an aberrant phenotype (surface CD3-,
but cytoplasmic CD3+) as detected by flow cytometric
analysis was used to distinguish RCD type I and II [10].
In total, 26 paired serum samples of CD patients at
time of disease activity (ACD group) and after normal-
isation of the CD associated antibodies upon a GFD
(GFD group), and of an additional 40 patients with com-
plicated CD at diagnosis were included. The latter group
consists of 12 RCDI, 16 RCDII and 12 EATL patients.
All procedures were in accordance with the regula-
tions of the medical ethics committee, and all patients
declared their informed consent to store and use their
blood samples collected for regular diagnostics for fur-
ther research.
Serum parameters: Enzyme linked immunosorbent assay
(ELISA)
Levels of cytokines IL-6, IL-8, IL-17 and IL-22 were
determined in serum using commercial ELISA kits (Peli-
kine-compact™, Sanquin, Amsterdam, The Netherlands),
according to the manufacturer’s instructions. Levels of
soluble CD25 (sCD25), soluble CD27 (sCD27), soluble
CTLA-4 (sCTLA-4), soluble MICA (sMICA) and
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commercial ELISA kit (Diaclone, Besancon, Cedex,
France), according to the manufacturer’s instructions.
Biochemical parameters
The concentration of C-reactive protein (CRP; g/L),
erythrocyte sedimentation rate (ESR; mm per 1 h),
leukocyte count (WBC; 10E9/L), albumin (g/L) and
haemoglobin (Hb; mmol/L) were extracted from the
hospital patient file for all patients included at time of
diagnosis.
Statistical analysis
Data were analysed and plotted using SPSS software
(SPSS Inc. Chicago, Illinois, USA), using non-parametric
tests as most variables examined in this study did not
appear to be normally distributed. A Wilcoxon signed-
rank test was used for pairwise comparison of the vari-
ability of immunological and biochemical parameters
among the ACD and GFD group. The latter groups were
individually compared to the complicated forms of CD
by using the Kruskal-Wallis non-parametric test to iden-
tify possible serum and biochemical differences in the
spectrum of CD. A receiver operating characteristic
(ROC) curve was made of all significantly different para-
meters to represent the trade off between the false nega-
tive and false positive rates. As a considerable number of
markers were determined, the level of significance was
set at highly significant (p < 0.001) and moderately sig-
nificant (0.001 < p <0.05).
Results
Table 1 shows the characteristics of the five subsets of
CD. Serum samples of 26 ACD patients at time of diag-
nosis and after remission of disease on a GFD were
included. In all patients CD associated antibodies
reverted to negative upon a GFD, and in 62% (16/26) a
biopsy was taken which revealed mucosal healing
(Marsh 0/I) in all those evaluated. Overall, 12 RCDI, 16
RCDII and 12 EATL patients were included. Significant
differences were found for cytokine profiles between the
five subsets of CD, as described in more detail below
(Figure 1A-I).
Active CD versus GFD
Serum levels of the inflammatory chemokine IL-8
(p = 0.00) and the T-cell activation factor sCD25 were
higher in active CD patients than in patients in remis-
sion on a GFD (p = 0.00, highly significant) as well as the
Th-17 lineage-defined cytokine IL-17 levels (p = 0.011,
moderately significant). Serum levels of IL-6, IL-22,
sCD27, sMICA, granzyme-B and sCTLA-4 were not sig-
nificantly elevated in the ACD group. In addition, levelsof CRP, ESR, albumin and leukocyte counts were similar
(data not shown).
Uncomplicated CD versus RCD
The serum levels of IL-8, IL-17 and sCD25 in RCD type
I and type II were comparable to those in the ACD
group, however, significantly lower levels were observed
in the GFD group. Moreover, in comparison to both
ACD and GFD patients, RCDII patients showed
increased levels of granzyme-B (p = 0.020; p = 0.016, both
moderately significant) and IL-6 (p = 0.018; p = 0.024, both
moderately significant), respectively. Furthermore, serum
levels of soluble CTLA-4 were lower in RCDII patients
than those in remission upon a GFD (p = 0.003, moderately
significant). Similar IL-22 serum levels were found in un-
complicated CD and RCDI-II. .
Comparison of the inflammatory parameters CRP, ESR
and leukocyte count did not reveal significant differences
between uncomplicated CD and RCDI-II. The concen-
tration of albumin was lower in both RCD subsets when
compared to ACD (p = 0.003, moderately significant)
and GFD (p = 0.000, highly significant; Figure 2).
The RCD complex
None of the markers tested was able to distinguish
RCDII from RCDI. Moreover, no significant differences
in levels of albumin or inflammatory parameters CRP,
ESR and leukocyte count were observed.
EATL versus ACD and RCD
The highest serum levels of IL-6 were observed in the
EATL group, were higher (p = 0.000, highly significant)
as compared to the ACD and GFD groups, as well as
higher (p = 0.002; p = 0.007, moderately significant) than
RCDI-II, respectively. Moreover, serum levels of IL-6
were clearly elevated in EATL over RCDII with an AUC
of 0.82 [95% CI: 0.649-0.971]. IL-6 levels in EATL
patients tended to correlate (0.45, p = 0.08) with CRP
levels, but not with IL-17 levels. Furthermore, serum
levels of sCD27 were decreased (moderately significant)
in EATL patients as compared to all other groups, ex-
cept RCDII in which (highly) significant (p = 0.000) dif-
ferences were found). Nevertheless, ROC analysis
resulted in a very low AUC. In addition, similar levels of
sMICA, granzyme-B and sCD25 were measured in
EATL and RCDI-II. However, the serum albumin con-
centration in EATL patients was lower (moderately sig-
nificant) than in ACD and both types of RCD (Figure 2).
Discussion
Currently, physicians are unable to predict who will de-
velop complicated CD. As invasive techniques are still
required to differentiate between uncomplicated and
complicated forms of CD, the purpose of the present
Table 1 Characteristics of the different groups in the spectrum of coeliac disease
SPECTRUM OF CD
ACD GFD RCDI RCDII EATL
(n = 26) (n = 26) (n = 12) (n = 16) (n = 12)
Age at CD (yr) Median, (SD;range) 42.5 45 50.5 61.5 61.5
(16; 21-76) ( 15; 21-77) (16; 19-69) (13; 27-74) (7; 48-66)
Age at RCD Median, (SD;range) - - 59 65 64
(11.5; 35-74) (10; 47-77) (8; 51-72)
Age at EATL Median, (SD;range) - - - - 65
(6; 51-74)
HLA-staus DQ2 heterozygous 10 7 8 7 3
DQ8 heterozygous 9 13 3
DQ2/8 heterozygous 3 2 1 3 2
DQ2 homozygous 4 4 3 6 4
Marsh 0 12 2
I 4
II 1
IIIA 11 8 9 5
IIIB 5 3 4 3
IIIC 10 1 3 1
ND 10
EMA Negative (-) 26 12 15 7
Dubious (+/-) 1 2
Weak positive (+) 3
Positive (++) 11 0
Stronglypositive(+++) 11 2
ND 1 1
TGA Negative 7 12 14 6
Dubious 2 2
Weak positive 8 1
Positive 6 1
Strongly positive 9 1
ND 3 19 1
Aberrant IELs (%) Mean (SD;range) - - 4,0 64 7
(6.0; 2-19) (23; 20-96) (32; 1-87)
EATL type Primary - - - - 4
Secondary 8
ACD: active coeliac disease patients; GFD: coeliac disease patients on a gluten-free diet; RCDI and II: refractory coeliac disease type I and II; EATL: enteropathy
associated T-cell lymphoma; EMA-A: endomysial antibodies; tTGA-A: tissue transglutaminase antibodies; IELs: intra-epithelial lymphocytes.
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eral blood to distinguish the various CD subsets. By
doing so, it may also provide insight in the potential dif-
ferences in underlying immunopathomechanisms of
these disease subsets.
The results could be biased by cytokine production
from different cellular sources in the peripheral blood,and therefore may not exactly mimic the intestinal in-
flammation [20]. However, other investigators have pre-
viously shown that blood cytokine profiles do reflect
intestinal mRNA expression in active CD patients
[2,21-23]. Care must be taken in case our findings are
extrapolated to other age groups, as it cannot be
excluded that normal values vary over age.






















































































Figure 1 A-I: Concentration of serum parameters in the different subsets of the CD spectrum: IL-6 (A) ; IL-8 (B); IL-17 (C); IL-22 (D);
sCD25 (E); sCD27 (F) ; sMICA (G); sCTLA-4 (H); granzyme-B (I). The dotted line corresponds with the upper level of the normal range.
Abbreviations: CD, coeliac disease; ACD, active coeliac disease; GFD, response upon a gluten-free diet; RCD I, refractory coeliac disease type I;
RCD II, refractory coeliac disease type II; EATL, enteropathy associated T-cell lymphoma.
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Our results are in keeping with previous studies report-
ing on serum cytokine levels in ACD patients, that
showed up-regulation of IL-8 [20,24], a chemokine pro-
duced by macrophages, epithelial as well as endothelial
cells that attracts leukocytes to a site of inflammation.
The same accounts for the observed elevated levels of
sCD25, that is cleaved off from the membranous CD25
(IL-2R-alpha) during T-cell activation [25-27]. Further-
more, the increased levels of the pro-inflammatory cyto-
kine IL-17 observed in the current study, supports the
view that Th17 cells that produce this particular cyto-
kine are involved in several auto-immune diseases and
are suggested to have a pathogenic role in CD [3-5]. In
contrast to the (pro-) inflammatory environmentalcharacteristics observed in this analysis and to previous
reports [20,26,28], the levels of IL-6, illustrative of an
acute phase response and a potent inducer of the Th17
pathway [29], were low and similar in both uncompli-
cated CD subsets. A clear explanation for these findings
is lacking, especially as strongly increased levels were
found in RCDII and EATL patients. Another cytokine
involved in gut inflammation is IL-22 that is produced
by Th17 and/or Th22 cells, where it is currently believed
to exert regulatory functions [30,31]. Elevated levels of
IL-22 have been found in the mucosa of Crohn’s disease
[32], but its role in CD is yet unclear [3,33]. Neverthe-
less, our results failed to reveal a correlation with IL-22
serum levels and disease activity or disease entity.
sCD27 serum levels are increased in T-cell mediated
active CD GFD RCDI RCDII EATL 





Figure 2 Concentration of albumin in the different subsets of
the CD spectrum. The concentration of albumin is significantly
higher in both the ACD (p = 0.003) and the GFD (p = 0.000) subset
compared to the complicated forms of CD. In EATL patients clearly
lower concentrations compared to both RCDI and II (p = 0.003 and
p = 0.037, respectively) were observed. Abbreviations: CD, coeliac
disease; ACD, active coeliac disease; GFD, response upon a
gluten-free diet; RCD I, refractory coeliac disease type I; RCD II,
refractory coeliac disease type II; EATL, enteropathy associated T-cell
lymphoma.
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However, the sCD27 levels were normal in ACD. This in
contrast to the previously reported increased production
of another lymphocyte activation marker sCD25. This
dissimilarity is remarkable as in SLE patients sCD25 and
sCD27 levels are strongly correlated during the whole
disease course [36].The RCD complex
Although, by general consent, RCD type I and II are
considered two related disease entities within the
spectrum of CD, it remains unclear if both diseases
share a similar pathogenesis responsible for the gluten-
independent inflammation. In keeping with the current
opinion, our results showed in both types of RCD simi-
lar inflammatory characteristics and T-cell activation
based on serum levels of IL-8, IL-17, IL-22 and sCD25,
respectively. On the other hand, a transition from RCDI
to RCDII has only been reported sporadically [16]. The-
oretically, granzyme-B is a suited parameter to differen-
tiate between RCD type I and II, since aberrant IELs are
clearly cytotoxic and express high amounts of intracellu-
lar granzyme-B [12]. Although increased levels of soluble
granzyme-B were observed in RCDII patients, these
were not significantly higher than in RCDI patients.RCD versus uncomplicated CD
Currently, it is unknown to what extent the gluten-
independent inflammation as generally observed in RCD
evolved from and/or differs from the gluten induced in-
flammation in active CD. In this study, the pro-
inflammatory T-cell response, including IL-8, IL-17,
sCD25, in both types of RCD and ACD patients shows
resemblance, with exception of evidently increased IL-6
levels in RCDII over active CD. This finding suggest a
higher inflammatory state in RCDII than in ACD, how-
ever, similar levels of the inflammatory parameters CRP,
ESR and leukocyte count were observed. In line with the
lack of intestinal inflammation in patients adhering to a
GFD, the pro-inflammatory response was significantly
lower as compared to the complicated forms of CD.
Interestingly, in comparison to ACD patients, RCDII
patients displayed a distinctive cytotoxic T-cell activation
profile based on elevated serum levels of granzyme-B.
The levels of these parameters observed in RCDI
patients did not differ from either ACD or RCDII
patients.Monitoring EATL development
RCDII patients carry a high risk to develop an EATL,
yet, so far no serum parameters for EATL development
have been identified, including efforts in the present
analysis. Based on the fact that EATL cells contain large
amounts of granzyme-B [13], these levels were measured
in the peripheral blood, but EATL patients did not con-
tain higher levels than active CD or RCD patients. Fur-
thermore, elevated levels of sCD27 [37] and sCD25 [38]
have been suggested to be associated with tumour bur-
den in some lymphoid neoplasia. Neoplastic lymphoid
cells in non-Hodgkin lymphoma express CD27 and are
considered responsible for the increased sCD27 produc-
tion [37]. The current analysis failed to show increased
sCD27 levels in EATL patients and thereby suggests that
EATL regards a distinct type of lymphoma and does not
aid in the identification of this particular lymphoma. In
contrast to a previous study showing elevated sCD25
levels in EATL [39], we found comparable levels of
sCD25 in EATL, RCDI-II and ACD. The same accounts
for sMICA, that is cleaved from membranous MICA
and has been shown to impair NKG2D mediated tumor
surveillance in epithelial tumors [40], as well as it has
shown potential as a prognostic parameter in hematopoietic
malignancies since increased levels of sMICA were
found in leukemia patients [41]. The only marker that
distinguished EATL from all other groups was IL-6
and its levels correlated with CRP levels, indicating a
more severe acute inflammatory response in EATL
patients that is distinctive from the other subsets of
CD. In accordance with our data, an association with
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been recognized almost twenty years ago [42].
Cytokine levels in comparison with other gastro-intestinal
diseases
Our data suggests that complicated CD is accompanied
by a higher pro-inflammatory state as compared to un-
complicated CD. To provide insight in the extend of this
inflammation, it can b compared to the cytokine profile
in other (small) intestinal disease, such as Crohn’s dis-
ease. Not only have elevated serum levels of IL-6 been
reported in this disease, but these levels appear even
higher than in complicated CD [43]. On the other hand,
IL-6 and IL-8 serum levels in Helicobacter Pylori
infected patients with peptic ulcer disease are not ele-
vated [44].
Clinical implication and potential application
Taken together, for daily clinical practice the results of
this analysis suggest that apart from detection of CD
associated antibodies and duodenal biopsies, other vari-
ables including IL-8, sCD25 and possibly IL-17, might
be helpful in monitoring inflammatory disease status
and differentiating between patients on a strict GFD and
those diagnosed as having RCDI-II. In case CD specific
antibodies remain mildly elevated, which is not rare in
RCDI-II patients, serum levels of granzyme-B could pos-
sibly serve as an additional markers to distinguish ACD
from RCDII, and will enable early intervention. However,
the currently accepted diagnostic work-up of RCD
remains required, pending prospective serum studies in-
cluding larger series of patients.
Conclusion
In conclusion, both types of RCD are characterised by
an ongoing and/or recurring inflammatory disease status
showing great resemblance to that observed in ACD
despite strict adherence to a GFD, yet differentiates itself
by elevated serum IL-6 concentrations in RCDII. Fur-
thermore, in addition to this increased pro-inflammatory
profile, RCDII reveals a distinctive cytotoxic T-cell acti-
vation profile as compared to ACD based on elevated
levels of granzyme-B, whereas RCDI does not. Although
no EATL-specific or -associated immunological para-
meters were found in this study, our ongoing efforts
may identify relevant markers. Further research will also
address the prospective and diagnostic value of the
serum variables identified is this study in order to ex-
pand the clinical application of (R)CD serology beyond
standard autoantibody testing.
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